<_ix3a_nonnumeric contextref="d20228K" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware
| <_ix3a_nonnumeric contextref="d20228K" name="dei:EntityFileNumber">1-11388
| <_ix3a_nonnumeric contextref="d20228K" name="dei:EntityTaxIdentificationNumber">04-3153858
| ||
(State or other jurisdiction of
incorporation)
|
(Commission File Number)
|
(I.R.S. Employer
Identification No.)
|
<_ix3a_nonnumeric contextref="d20228K" name="dei:EntityAddressAddressLine1">345 Inverness Drive South, Building B, Suite 250
<_ix3a_nonnumeric contextref="d20228K" name="dei:EntityAddressCityOrTown">Englewood, <_ix3a_nonnumeric contextref="d20228K" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Colorado
| <_ix3a_nonnumeric contextref="d20228K" name="dei:EntityAddressPostalZipCode">80112
| |
(Address of principal executive offices)
|
(Zip Code)
|
Title of each class
|
Trading symbol(s)
|
Name of each exchange on which registered
|
<_ix3a_nonnumeric contextref="d20228K" name="dei:Security12bTitle">Common Stock
| <_ix3a_nonnumeric contextref="d20228K" name="dei:TradingSymbol">VIVE
| <_ix3a_nonnumeric contextref="d20228K" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq Capital Market
|
<_ix3a_nonnumeric contextref="d20228K" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications">☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
<_ix3a_nonnumeric contextref="d20228K" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial">☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
<_ix3a_nonnumeric contextref="d20228K" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer">☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
<_ix3a_nonnumeric contextref="d20228K" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer">☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item7.01. |
Regulation FD Disclosure. |
Item9.01. |
Financial Statements and Exhibits. |
Exhibit
No.
|
Description
| |
99.1
| Press Release issued by the Company on September 15, 2022, furnished herewith. | |
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
Date: September 15, 2022
|
Viveve Medical, Inc.
| ||
By:
|
/s/ Scott Durbin
| ||
Scott Durbin
| |||
Chief Executive Officer
|
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Viveve Medical Inc. published this content on 15 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 September 2022 12:39:01 UTC.